Rauwolfia vomitoria extract suppresses benign prostatic hyperplasia by inducing autophagic apoptosis through endoplasmic reticulum stress.


Journal

BMC complementary medicine and therapies
ISSN: 2662-7671
Titre abrégé: BMC Complement Med Ther
Pays: England
ID NLM: 101761232

Informations de publication

Date de publication:
05 May 2022
Historique:
received: 05 12 2021
accepted: 25 04 2022
entrez: 5 5 2022
pubmed: 6 5 2022
medline: 10 5 2022
Statut: epublish

Résumé

The current drug treatments for benign prostatic hyperplasia (BPH) have negative side effects. Therefore, it is important to find effective alternative therapies with significantly fewer side effects. Our previous study revealed that Rauwolfia vomitoria (RWF) root bark extract reversed BPH development in a rat model. However, the molecular mechanism of its inhibitory effects on BPH remains largely unknown. BPH-1 and WPMY-1 cell lines derived from BPH epithelial and prostatic stromal compartments were selected to investigate how RWF extract inhibits BPH in vitro by MTT and flow cytometry assays. Microarray, quantitative real-time PCR, immunoblotting, and GFP-LC3 immunofluorescence assays were performed to evaluate the effects of RWF extract on endoplasmic reticulum stress (ER stress) and autophagic apoptosis pathways in two cell lines. A human BPH ex vivo explant assay was also employed for validation. RWF extract treatment decreased cell viability and induced apoptotic cell death in both BPH-1 and WPMY-1 cells in a concentration-dependent manner with the increase of pro-apoptotic PCDC4 protein. RWF extract induced autophagy by enhancing the levels of autophagic genes (ULK2 and SQSTM1/p62) and the LC3II:LC3I ratio, with the increase of GFP-LC3 puncta. Moreover, RWF extract activated PERK- and ATF6-associated ER stress pathways by inducing the transcriptional levels of EIF2AK3/PERK, DDIT3/CHOP and ATF6, accompanied by the reduction of BiP protein level, but not its mRNA level. Another ER stress pathway was not induced by RWF extract, as manifested by the lack of XBP1 splicing. Pharmacological inhibition of autophagy by 3-methyladenine abrogated apoptosis but not ER stress; while inhibition of ER stress by 4-phenylbutyrate alleviated the induction of autophagy and apoptosis. In addition, pretreatments with either 3-methyladenine or 4-phenylbutyrate suppressed RWF extract-induced cytotoxicity. Notably, the inductions of PERK- and ATF6-related stress pathways and autophagic apoptosis were confirmed in a human BPH ex vivo explant. Our data have demonstrated that RWF extract significantly suppressed the viabilities of BPH epithelial cells and BPH myofibroblasts by inducing apoptosis via upregulating ER stress and autophagy. These data indicate that RWF extract is a potential novel alternative therapeutic approach for BPH.

Sections du résumé

BACKGROUND BACKGROUND
The current drug treatments for benign prostatic hyperplasia (BPH) have negative side effects. Therefore, it is important to find effective alternative therapies with significantly fewer side effects. Our previous study revealed that Rauwolfia vomitoria (RWF) root bark extract reversed BPH development in a rat model. However, the molecular mechanism of its inhibitory effects on BPH remains largely unknown.
METHODS METHODS
BPH-1 and WPMY-1 cell lines derived from BPH epithelial and prostatic stromal compartments were selected to investigate how RWF extract inhibits BPH in vitro by MTT and flow cytometry assays. Microarray, quantitative real-time PCR, immunoblotting, and GFP-LC3 immunofluorescence assays were performed to evaluate the effects of RWF extract on endoplasmic reticulum stress (ER stress) and autophagic apoptosis pathways in two cell lines. A human BPH ex vivo explant assay was also employed for validation.
RESULTS RESULTS
RWF extract treatment decreased cell viability and induced apoptotic cell death in both BPH-1 and WPMY-1 cells in a concentration-dependent manner with the increase of pro-apoptotic PCDC4 protein. RWF extract induced autophagy by enhancing the levels of autophagic genes (ULK2 and SQSTM1/p62) and the LC3II:LC3I ratio, with the increase of GFP-LC3 puncta. Moreover, RWF extract activated PERK- and ATF6-associated ER stress pathways by inducing the transcriptional levels of EIF2AK3/PERK, DDIT3/CHOP and ATF6, accompanied by the reduction of BiP protein level, but not its mRNA level. Another ER stress pathway was not induced by RWF extract, as manifested by the lack of XBP1 splicing. Pharmacological inhibition of autophagy by 3-methyladenine abrogated apoptosis but not ER stress; while inhibition of ER stress by 4-phenylbutyrate alleviated the induction of autophagy and apoptosis. In addition, pretreatments with either 3-methyladenine or 4-phenylbutyrate suppressed RWF extract-induced cytotoxicity. Notably, the inductions of PERK- and ATF6-related stress pathways and autophagic apoptosis were confirmed in a human BPH ex vivo explant.
CONCLUSIONS CONCLUSIONS
Our data have demonstrated that RWF extract significantly suppressed the viabilities of BPH epithelial cells and BPH myofibroblasts by inducing apoptosis via upregulating ER stress and autophagy. These data indicate that RWF extract is a potential novel alternative therapeutic approach for BPH.

Identifiants

pubmed: 35513857
doi: 10.1186/s12906-022-03610-4
pii: 10.1186/s12906-022-03610-4
pmc: PMC9074266
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

125

Subventions

Organisme : National Natural Science Foundation of China
ID : 81872373

Informations de copyright

© 2022. The Author(s).

Références

Drug Des Devel Ther. 2017 Oct 11;11:2969-2979
pubmed: 29066868
Semin Cancer Biol. 2020 Nov;66:116-128
pubmed: 31838023
Oncol Rep. 2018 Dec;40(6):3144-3154
pubmed: 30272287
Sci Rep. 2019 Dec 23;9(1):19703
pubmed: 31873149
Cell Death Dis. 2018 Mar 22;9(4):431
pubmed: 29568063
Adv Exp Med Biol. 2019;1206:167-177
pubmed: 31776985
Int J Urol. 2014 Feb;21(2):195-9
pubmed: 23819759
J Cell Mol Med. 2021 Jun;25(12):5753-5768
pubmed: 33982874
BMC Complement Med Ther. 2020 May 16;20(1):150
pubmed: 32416730
Differentiation. 2011 Nov-Dec;82(4-5):200-10
pubmed: 21664759
FEBS J. 2019 Jan;286(2):241-278
pubmed: 30027602
Front Immunol. 2019 Jan 04;9:3083
pubmed: 30662442
Am J Manag Care. 2006 Apr;12(5 Suppl):S122-8
pubmed: 16613526
Integr Med (Encinitas). 2015 Jun;14(3):40-6
pubmed: 26770146
Nat Rev Mol Cell Biol. 2018 Jun;19(6):349-364
pubmed: 29618831
Org Lett. 2017 Aug 4;19(15):3998-4001
pubmed: 28718654
World J Urol. 2019 Jul;37(7):1293-1296
pubmed: 30805683
BJU Int. 2021 Apr;127(4):389-399
pubmed: 32893964
Essays Biochem. 2017 Dec 12;61(6):625-635
pubmed: 29233873
J Altern Complement Med. 2017 Aug;23(8):599-606
pubmed: 28436684
PLoS Comput Biol. 2021 Feb 9;17(2):e1008696
pubmed: 33561121
Oncotarget. 2017 Feb 7;8(31):50904-50910
pubmed: 28881614
Can J Urol. 2012 Oct;19 Suppl 1:10-7
pubmed: 23089343
J Integr Med. 2021 May;19(3):258-264
pubmed: 33341427
Phytochem Anal. 2016 Sep;27(5):296-303
pubmed: 27437669
Front Oncol. 2020 Oct 23;10:576615
pubmed: 33194689
Zhonghua Yi Xue Za Zhi. 2008 May 13;88(18):1284-8
pubmed: 18844105
Sci Adv. 2020 Jul 15;6(29):eabb9614
pubmed: 32832649
Front Oncol. 2020 Oct 07;10:578418
pubmed: 33117715
Chin Med J (Engl). 2017 Aug 20;130(16):1953-1960
pubmed: 28776548
Adv Exp Med Biol. 2017;1043:473-526
pubmed: 29224108
J Ethnopharmacol. 2020 Mar 25;250:112446
pubmed: 31812646
Exp Cell Biol. 1982;50(2):79-87
pubmed: 7075859
J Cell Physiol. 2018 May;233(5):3867-3874
pubmed: 28777470
BJU Int. 2011 Mar;107(6):876-80
pubmed: 21265993
Mini Rev Med Chem. 2017;17(14):1346-1363
pubmed: 27337973
Pharmacology. 2021;106(9-10):488-497
pubmed: 34237728
Cancer Discov. 2012 Dec;2(12):1134-49
pubmed: 22993403
Nucleic Acids Res. 2013 Sep;41(16):7683-99
pubmed: 23804767
Curr Ther Res Clin Exp. 2013 Dec;75:8-14
pubmed: 24465036
Annu Rev Pathol. 2015;10:173-94
pubmed: 25387057
Cell Prolif. 2019 May;52(3):e12590
pubmed: 30883989
Curr Cancer Drug Targets. 2017;17(8):722-734
pubmed: 28359246
Biochem Biophys Res Commun. 2015 Sep 4;464(4):1107-1112
pubmed: 26212439
Science. 2010 Mar 26;327(5973):1638-42
pubmed: 20339072
Int J Oncol. 2006 Nov;29(5):1065-73
pubmed: 17016636
Clin Cancer Res. 2012 Jul 1;18(13):3562-70
pubmed: 22573351
Oxid Med Cell Longev. 2019 Feb 3;2019:5729710
pubmed: 30863482

Auteurs

Guifang Huang (G)

School of Chinese Materia Medica, Nanjing University of Chinese Medicine, 138 Xianlin Avenue, Nanjing, 210023, Jiangsu, China.
Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai, 201203, China.

Xiao He (X)

School of Chinese Materia Medica, Nanjing University of Chinese Medicine, 138 Xianlin Avenue, Nanjing, 210023, Jiangsu, China.
Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai, 201203, China.

Zesheng Xue (Z)

Model Animal Research Center of Nanjing University, 12 Xuefu Road, Nanjing, 210061, Jiangsu, China.

Yiming Long (Y)

Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai, 201203, China.
University of Chinese Academy of Sciences, No.19(A) Yuquan Road, Beijing, 100049, China.

Jiakuan Liu (J)

Department of Laboratory Animal Science, Fudan University, 130 Dong'an Road, Shanghai, 200032, China.

Jinming Cai (J)

Department of Urology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, 100 Haining Road, Shanghai, 200080, China.

Pengfei Tang (P)

Department of Urology, Shanghai General Hospital of Nanjing Medical University, Shanghai, 200080, China.

Bangmin Han (B)

Department of Urology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, 100 Haining Road, Shanghai, 200080, China.

Bing Shen (B)

Department of Urology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, 100 Haining Road, Shanghai, 200080, China.
Department of Urology, Shanghai General Hospital of Nanjing Medical University, Shanghai, 200080, China.

Ruimin Huang (R)

School of Chinese Materia Medica, Nanjing University of Chinese Medicine, 138 Xianlin Avenue, Nanjing, 210023, Jiangsu, China. rmhuang@simm.ac.cn.
Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai, 201203, China. rmhuang@simm.ac.cn.
University of Chinese Academy of Sciences, No.19(A) Yuquan Road, Beijing, 100049, China. rmhuang@simm.ac.cn.

Jun Yan (J)

Department of Laboratory Animal Science, Fudan University, 130 Dong'an Road, Shanghai, 200032, China. yan_jun@fudan.edu.cn.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH